vs

Side-by-side financial comparison of ABVC BIOPHARMA, INC. (ABVC) and Align Technology (ALGN). Click either name above to swap in a different company.

Align Technology is the larger business by last-quarter revenue ($1.0B vs $796.0K, roughly 1316.1× ABVC BIOPHARMA, INC.). Align Technology runs the higher net margin — 13.0% vs -256.6%, a 269.6% gap on every dollar of revenue. On growth, ABVC BIOPHARMA, INC. posted the faster year-over-year revenue change (104.5% vs 5.3%). Over the past eight quarters, ABVC BIOPHARMA, INC.'s revenue compounded faster (1041.5% CAGR vs 2.5%).

ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandib...

ABVC vs ALGN — Head-to-Head

Bigger by revenue
ALGN
ALGN
1316.1× larger
ALGN
$1.0B
$796.0K
ABVC
Growing faster (revenue YoY)
ABVC
ABVC
+99.2% gap
ABVC
104.5%
5.3%
ALGN
Higher net margin
ALGN
ALGN
269.6% more per $
ALGN
13.0%
-256.6%
ABVC
Faster 2-yr revenue CAGR
ABVC
ABVC
Annualised
ABVC
1041.5%
2.5%
ALGN

Income Statement — Q3 2025 vs Q4 2025

Metric
ABVC
ABVC
ALGN
ALGN
Revenue
$796.0K
$1.0B
Net Profit
$-2.0M
$135.8M
Gross Margin
100.0%
65.3%
Operating Margin
-246.8%
14.8%
Net Margin
-256.6%
13.0%
Revenue YoY
104.5%
5.3%
Net Profit YoY
-417.4%
30.8%
EPS (diluted)
$-0.09
$1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABVC
ABVC
ALGN
ALGN
Q4 25
$1.0B
Q3 25
$796.0K
$995.7M
Q2 25
$1.0B
Q1 25
$979.3M
Q4 24
$2.0K
$995.2M
Q3 24
$389.3K
$977.9M
Q2 24
$117.1K
$1.0B
Q1 24
$1.2K
$997.4M
Net Profit
ABVC
ABVC
ALGN
ALGN
Q4 25
$135.8M
Q3 25
$-2.0M
$56.8M
Q2 25
$124.6M
Q1 25
$93.2M
Q4 24
$-731.6K
$103.8M
Q3 24
$-394.8K
$116.0M
Q2 24
$-942.3K
$96.6M
Q1 24
$-2.8M
$105.0M
Gross Margin
ABVC
ABVC
ALGN
ALGN
Q4 25
65.3%
Q3 25
100.0%
64.2%
Q2 25
69.9%
Q1 25
69.5%
Q4 24
100.0%
70.0%
Q3 24
99.9%
69.7%
Q2 24
99.8%
70.3%
Q1 24
77.0%
70.0%
Operating Margin
ABVC
ABVC
ALGN
ALGN
Q4 25
14.8%
Q3 25
-246.8%
9.7%
Q2 25
16.1%
Q1 25
13.4%
Q4 24
-35837.4%
14.5%
Q3 24
-77.7%
16.6%
Q2 24
-734.2%
14.3%
Q1 24
-235539.8%
15.5%
Net Margin
ABVC
ABVC
ALGN
ALGN
Q4 25
13.0%
Q3 25
-256.6%
5.7%
Q2 25
12.3%
Q1 25
9.5%
Q4 24
-37211.3%
10.4%
Q3 24
-101.4%
11.9%
Q2 24
-804.4%
9.4%
Q1 24
-235203.2%
10.5%
EPS (diluted)
ABVC
ABVC
ALGN
ALGN
Q4 25
$1.88
Q3 25
$-0.09
$0.78
Q2 25
$1.72
Q1 25
$1.27
Q4 24
$-0.02
$1.40
Q3 24
$-0.03
$1.55
Q2 24
$-0.08
$1.28
Q1 24
$-0.29
$1.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABVC
ABVC
ALGN
ALGN
Cash + ST InvestmentsLiquidity on hand
$257.2K
$1.1B
Total DebtLower is stronger
Stockholders' EquityBook value
$12.1M
$4.0B
Total Assets
$21.2M
$6.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABVC
ABVC
ALGN
ALGN
Q4 25
$1.1B
Q3 25
$257.2K
$1.0B
Q2 25
$901.2M
Q1 25
$873.0M
Q4 24
$313.1K
$1.0B
Q3 24
$208.2K
$1.0B
Q2 24
$200.0K
$761.4M
Q1 24
$106.4K
$865.8M
Stockholders' Equity
ABVC
ABVC
ALGN
ALGN
Q4 25
$4.0B
Q3 25
$12.1M
$4.0B
Q2 25
$3.9B
Q1 25
$3.8B
Q4 24
$1.2M
$3.9B
Q3 24
$1.6M
$3.9B
Q2 24
$1.8M
$3.8B
Q1 24
$1.7M
$3.8B
Total Assets
ABVC
ABVC
ALGN
ALGN
Q4 25
$6.2B
Q3 25
$21.2M
$6.2B
Q2 25
$6.2B
Q1 25
$6.1B
Q4 24
$7.5M
$6.2B
Q3 24
$7.8M
$6.4B
Q2 24
$8.0M
$6.2B
Q1 24
$8.0M
$6.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABVC
ABVC
ALGN
ALGN
Operating Cash FlowLast quarter
$-964.7K
$223.2M
Free Cash FlowOCF − Capex
$187.3M
FCF MarginFCF / Revenue
17.9%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters
$490.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABVC
ABVC
ALGN
ALGN
Q4 25
$223.2M
Q3 25
$-964.7K
$188.7M
Q2 25
$128.7M
Q1 25
$52.7M
Q4 24
$-702.1K
$286.1M
Q3 24
$60.2K
$263.7M
Q2 24
$-211.4K
$159.8M
Q1 24
$-955.8K
$28.7M
Free Cash Flow
ABVC
ABVC
ALGN
ALGN
Q4 25
$187.3M
Q3 25
$169.0M
Q2 25
$107.2M
Q1 25
$27.4M
Q4 24
$263.1M
Q3 24
$233.9M
Q2 24
$106.4M
Q1 24
$19.3M
FCF Margin
ABVC
ABVC
ALGN
ALGN
Q4 25
17.9%
Q3 25
17.0%
Q2 25
10.6%
Q1 25
2.8%
Q4 24
26.4%
Q3 24
23.9%
Q2 24
10.3%
Q1 24
1.9%
Capex Intensity
ABVC
ABVC
ALGN
ALGN
Q4 25
3.4%
Q3 25
2.0%
Q2 25
2.1%
Q1 25
2.6%
Q4 24
2.3%
Q3 24
3.0%
Q2 24
5.2%
Q1 24
0.9%
Cash Conversion
ABVC
ABVC
ALGN
ALGN
Q4 25
1.64×
Q3 25
3.33×
Q2 25
1.03×
Q1 25
0.57×
Q4 24
2.76×
Q3 24
2.27×
Q2 24
1.66×
Q1 24
0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons